[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0209986A - Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias - Google Patents

Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias

Info

Publication number
BR0209986A
BR0209986A BR0209986-1A BR0209986A BR0209986A BR 0209986 A BR0209986 A BR 0209986A BR 0209986 A BR0209986 A BR 0209986A BR 0209986 A BR0209986 A BR 0209986A
Authority
BR
Brazil
Prior art keywords
treatment
combination
agonist
anticholinergic agent
obstructive airway
Prior art date
Application number
BR0209986-1A
Other languages
English (en)
Inventor
Roisin A Armstrong
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0209986A publication Critical patent/BR0209986A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"AGONISTA DE A2A EM COMBINAçãO COM UM AGENTE ANTICOLINéRGICO, PARA O TRATAMENTO DE DOENçAS OBSTRUTIVAS DAS VIAS RESPIRATóRIAS". A presente invenção refere-se a uma combinação de um agonista do receptor A~ 2a~ de adenosina seletivo e um agente anticolinérgico para administração simultânea, seq³encial ou separada pela via inalada no tratamento de uma doença obstrutiva das vias respiratórias ou outra doença inflamatória, com a condição de que o agente anticolinérgico nao seja um sal de tiotrópio.
BR0209986-1A 2001-05-25 2002-05-24 Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias BR0209986A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition
PCT/EP2002/005725 WO2002096462A1 (en) 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Publications (1)

Publication Number Publication Date
BR0209986A true BR0209986A (pt) 2004-04-06

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209986-1A BR0209986A (pt) 2001-05-25 2002-05-24 Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias

Country Status (22)

Country Link
US (1) US20040171576A1 (pt)
EP (1) EP1395287A1 (pt)
KR (1) KR20030097901A (pt)
CN (1) CN1535161A (pt)
AP (1) AP2003002911A0 (pt)
BG (1) BG108383A (pt)
BR (1) BR0209986A (pt)
CA (1) CA2448086A1 (pt)
CO (1) CO5540324A2 (pt)
CZ (1) CZ20033126A3 (pt)
EE (1) EE200300586A (pt)
HU (1) HUP0400029A2 (pt)
IL (1) IL158774A0 (pt)
MA (1) MA27028A1 (pt)
MX (1) MXPA03010787A (pt)
NO (1) NO20035202D0 (pt)
OA (1) OA12609A (pt)
PA (1) PA8546101A1 (pt)
PL (1) PL366899A1 (pt)
SK (1) SK14302003A3 (pt)
SV (1) SV2003001055A (pt)
WO (1) WO2002096462A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
EP2266994B1 (en) 2004-08-02 2013-04-03 University Of Virginia Patent Foundation 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ATE331726T1 (de) * 1998-10-16 2006-07-15 Pfizer Adenine-derivate
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
KR20030097901A (ko) 2003-12-31
NO20035202D0 (no) 2003-11-24
CZ20033126A3 (cs) 2004-09-15
MA27028A1 (fr) 2004-12-20
US20040171576A1 (en) 2004-09-02
SV2003001055A (es) 2003-11-14
HUP0400029A2 (hu) 2004-04-28
BG108383A (bg) 2004-08-31
EE200300586A (et) 2004-04-15
CA2448086A1 (en) 2002-12-05
PL366899A1 (en) 2005-02-07
AP2003002911A0 (en) 2003-12-31
WO2002096462A1 (en) 2002-12-05
OA12609A (en) 2006-06-09
EP1395287A1 (en) 2004-03-10
MXPA03010787A (es) 2004-03-02
SK14302003A3 (sk) 2004-08-03
CO5540324A2 (es) 2005-07-29
PA8546101A1 (es) 2003-12-10
CN1535161A (zh) 2004-10-06
IL158774A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
BR0209986A (pt) Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias
BR0209992A (pt) Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias
BR0008039A (pt) Combinações de formoterol e um sal de tiotrópio
Sabater et al. Aerosolization of P2Y2-receptor agonists enhances mucociliary clearance in sheep
BR0213397A (pt) Método para suprimento de uma mistura de gases a um paciente, sistema para suprimento de gás a um paciente, usos de halotano, de enflurano, de isoflurano, de sevoflurano e de desflurano no sistema para suprimento, sistema para suprimento de medicamento, e, método para suprimento de medicamento terapêutico
BR0115910A (pt) Compostos orgânicos
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
BRPI0514536A (pt) uso de oligossacarìdeos não-digerìveis e sacarìdeo de galactose digerìvel, e, composição adequada para o tratamento e/ou prevenção de infecções do trato respiratório e/ou doença de infecção do trato respiratório
DE60301647D1 (de) System für langandauernde Sauerstofftherapie
Bleecker et al. The mechanism of rapid, shallow breathing after inhaling histamine aerosol in exercising dogs
Brosnan et al. Effects of hypercapnic hyperpnea on recovery from isoflurane or sevoflurane anesthesia in horses
BR0309595A (pt) Injeção produzida a partir de ixeris sonchifolia hance para o tratamento de doenças vasculares cardiocerebrais e doenças de fundo, e método para a produção da mesma
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
Wilson et al. Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice
BR0214998A (pt) Combinações farmacêuticas de agonistas do receptor da adenosina a-2a e do receptor adrenérgico beta-2
UY27308A1 (es) Un agonista de a2a en combinación con un agente anticolinérgico para el tratamiento de enfermedades obstructivas de las vias aéreas
ECSP034863A (es) Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
Baumert Xenon-based anesthesia: theory and practice
BR0004813A (pt) Constructos vesiculares marcados para citoproteção e tratamento de infecções por h. pylori
UY27565A1 (es) Combinación farmacéutica.
Junor et al. Lack of a role for cyclic nucleotide gated cation channels in lung liquid absorption in fetal sheep
BR0214776A (pt) Combinação de um inibidor seletivo de pde4 e um agonista do receptor adrenérgico beta-2
Díaz-Lobato et al. High-flow nasal oxygen is not an oxygen therapy device
UY27307A1 (es) Un inhibidor de pde4 y un agente anticolinérgico en combinación para tratar enfermedades obstructivas de vías respiratorias
HN2002000128A (es) Un agonista de a2a en combinación con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A , 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.